Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and China Pharmaceutical University presented the discovery of novel orally bioavailable inhibitors of transient receptor potential canonical channels 4 and 5 (TRPC4/5), being developed for the treatment of depression and anxiety.
Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and EGFR (del19/T790M/C797S triple mutant) inhibitors reported to be useful for the treatment of cancer.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Zhejiang University have jointly discovered N2-3-fluoro-5-substituted phenyl-2-aminopyrimidine derivatives.
Aromatase inhibitors (AI) are among the most widely used therapies in the treatment of breast tumors expressing estrogen receptor α (ERα). Alone or in combination with other agents, they are the standard of care for hormone receptor-positive tumors.
ENPP1 contributes to establishing an immunosuppressive tumor microenvironment by blocking the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, which is critical in antitumor immunity. The inhibition of ENPP1 is an emerging strategy under exploration for cancer immunotherapy.
Liver diseases are responsible for around two million deaths every year. Among them, hepatocellular carcinoma (HCC), particularly at late stages, presents limited therapeutic options and a dismal survival rate.
Researchers at China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have disclosed short transient receptor potential channel 5 (TRPC5) and/or short transient receptor potential channel 4 (TRPC4) ligands reported to be useful for the treatment of cancer and more.
Researchers at China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have disclosed short transient receptor potential channel 5 (TRPC5) and/or short transient receptor potential channel 4 (TRPC4) ligands reported to be useful for the treatment of cancer and more.
Thyroid hormone receptor-interacting protein 13 (TRIP13) is overexpressed in multiple myeloma (MM), where it is associated with progression and poor prognosis.
Nanjing Medical University and the Shanghai Institutes of Materia Medica and Nutrition & Health of the Chinese Academy of Sciences have prepared and tested 1,2,3,4-tetrahydropyridone compounds acting as Jumonji domain-containing protein 1C (JMJD1C; TRIP-8) inhibitors. As such, they are described as potentially useful for the treatment of cancer.
